Smith & Nephew’s (SN) “Buy” Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reaffirmed their buy rating on shares of Smith & Nephew (LON:SN) in a research note released on Wednesday, MarketBeat reports. Jefferies Financial Group currently has a GBX 1,500 price objective on the stock.

SN has been the topic of several other reports. Shore Capital Group reaffirmed a “buy” rating and issued a GBX 1,000 target price on shares of Smith & Nephew in a research note on Tuesday, July 21st. Citigroup lowered shares of Smith & Nephew to a “buy” rating in a report on Friday, July 10th. Royal Bank Of Canada restated a “sector perform” rating and issued a GBX 1,350 price objective on shares of Smith & Nephew in a research report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,400 price objective on shares of Smith & Nephew in a research note on Thursday, July 30th. Finally, UBS Group reissued a “neutral” rating and issued a GBX 1,300 target price on shares of Smith & Nephew in a research note on Tuesday, May 5th. Three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of GBX 1,172.56.

Smith & Nephew Stock Performance

Shares of SN stock opened at GBX 1,113 on Wednesday. The company has a market capitalization of £12.20 billion, a P/E ratio of 40.07, a P/E/G ratio of 0.46 and a beta of 0.69. The company has a quick ratio of 0.84, a current ratio of 2.14 and a debt-to-equity ratio of 73.07. The company has a fifty day moving average of GBX 1,135.36 and a 200 day moving average of GBX 1,192.51.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.